Home
>
US Stocks
>
Exact Sciences Corporation

Exact Sciences Corporation (EXAS)

$83.84

[object Object]

([object Object]%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Exact Sciences Corporation

  • Increasing Revenue

    Revenue is up for the last 9 quarters, 402.07M → 602.45M (in $), with an average increase of 4.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -220.61M → -74.15M (in $), with an average increase of 26.3% per quarter

  • Vs IDXX

    In the last 3 years, Idexx Laboratories, Inc. has given 51.8% return, outperforming this stock by 52.9%

Performance

  • $82.49
    $84.74
    $83.84
    downward going graph

    1.61%

    Downside

    Day's Volatility :2.66%

    Upside

    1.06%

    downward going graph
  • $29.27
    $85.82
    $83.84
    downward going graph

    65.09%

    Downside

    52 Weeks Volatility :65.89%

    Upside

    2.31%

    downward going graph

Returns

PeriodExact Sciences CorporationSector (Health Care)Index (Russel 2000)
3 Months
25.08%
0.9%
-8.3%
6 Months
84.06%
-6.8%
-6.5%
1 Year
79.57%
0.4%
-6.1%
3 Years
-1.13%
28.3%
21.8%

Highlights

Market Capitalization
15.1B
Book Value
$17.0
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.0
PEG Ratio
-1.07
Wall Street Target Price
86.52
Profit Margin
-23.49%
Operating Margin TTM
-22.87%
Return On Assets TTM
-4.92%
Return On Equity TTM
-16.36%
Revenue TTM
2.2B
Revenue Per Share TTM
12.4
Quarterly Revenue Growth YOY
23.799999999999997%
Gross Profit TTM
1.5B
EBITDA
-303.6M
Diluted Eps TTM
-3.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.0
EPS Estimate Next Year
-1.31
EPS Estimate Current Quarter
-0.75
EPS Estimate Next Quarter
-0.69

Analyst Recommendation

Buy
    73%Buy
    26%Hold
    0
    0%Sell
Based on 26 Wall street analysts offering stock ratings for Exact Sciences Corporation(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
20
21
Hold
7
6
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3.2%

Current $83.84
Target $86.52

Company Financials

FY17Y/Y Change
Revenue
266.0M
↑ 167.66%
Net Income
-114.4M
↓ 31.59%
Net Profit Margin
-43.01%
↑ 125.25%
FY18Y/Y Change
Revenue
454.5M
↑ 70.86%
Net Income
-175.1M
↑ 53.11%
Net Profit Margin
-38.54%
↑ 4.47%
FY19Y/Y Change
Revenue
876.3M
↑ 92.82%
Net Income
-84.0M
↓ 52.04%
Net Profit Margin
-9.59%
↑ 28.95%
FY20Y/Y Change
Revenue
1.5B
↑ 70.19%
Net Income
-848.5M
↑ 910.24%
Net Profit Margin
-56.9%
↓ 47.31%
FY21Y/Y Change
Revenue
1.8B
↑ 18.49%
Net Income
-595.6M
↓ 29.81%
Net Profit Margin
-33.71%
↑ 23.19%
FY22Y/Y Change
Revenue
2.1B
↑ 17.95%
Net Income
-623.5M
↑ 4.68%
Net Profit Margin
-29.91%
↑ 3.8%
Q4 FY21Q/Q Change
Revenue
473.8M
↑ 3.82%
Net Income
-220.6M
↑ 32.15%
Net Profit Margin
-46.56%
↓ 9.98%
Q1 FY22Q/Q Change
Revenue
486.6M
↑ 2.69%
Net Income
-180.9M
↓ 17.98%
Net Profit Margin
-37.19%
↑ 9.37%
Q2 FY22Q/Q Change
Revenue
521.6M
↑ 7.21%
Net Income
-166.1M
↓ 8.22%
Net Profit Margin
-31.83%
↑ 5.36%
Q3 FY22Q/Q Change
Revenue
523.1M
↑ 0.27%
Net Income
-148.8M
↓ 10.42%
Net Profit Margin
-28.44%
↑ 3.39%
Q4 FY22Q/Q Change
Revenue
553.0M
↑ 5.72%
Net Income
-127.7M
↓ 14.13%
Net Profit Margin
-23.1%
↑ 5.34%
Q1 FY23Q/Q Change
Revenue
602.5M
↑ 8.94%
Net Income
-74.2M
↓ 41.95%
Net Profit Margin
-12.31%
↑ 10.79%
FY17Y/Y Change
Total Assets
598.6M
↑ 58.75%
Total Liabilities
78.1M
↑ 87.19%
FY18Y/Y Change
Total Assets
1.5B
↑ 154.61%
Total Liabilities
843.1M
↑ 978.91%
FY19Y/Y Change
Total Assets
3.5B
↑ 130.03%
Total Liabilities
1.2B
↑ 44.44%
FY20Y/Y Change
Total Assets
4.9B
↑ 40.49%
Total Liabilities
2.1B
↑ 72.59%
FY21Y/Y Change
Total Assets
6.7B
↑ 35.73%
Total Liabilities
3.3B
↑ 56.89%
FY22Y/Y Change
Total Assets
6.2B
↓ 6.85%
Total Liabilities
3.2B
↓ 3.44%
Q4 FY21Q/Q Change
Total Assets
6.7B
↑ 0.46%
Total Liabilities
3.3B
↑ 3.14%
Q1 FY22Q/Q Change
Total Assets
6.5B
↓ 2.91%
Total Liabilities
3.2B
↓ 1.97%
Q2 FY22Q/Q Change
Total Assets
6.4B
↓ 0.82%
Total Liabilities
3.2B
↓ 0.14%
Q3 FY22Q/Q Change
Total Assets
6.3B
↓ 2.03%
Total Liabilities
3.2B
↓ 0.93%
Q4 FY22Q/Q Change
Total Assets
6.2B
↓ 1.26%
Total Liabilities
3.2B
↓ 0.44%
Q1 FY23Q/Q Change
Total Assets
6.3B
↑ 1.24%
Total Liabilities
3.2B
↑ 1.98%
FY17Y/Y Change
Operating Cash Flow
-71.7M
↓ 44.86%
Investing Cash Flow
-160.8M
↑ 1296.0%
Financing Cash Flow
261.0M
↑ 74.45%
FY18Y/Y Change
Operating Cash Flow
-69.3M
↓ 3.34%
Investing Cash Flow
-781.9M
↑ 386.25%
Financing Cash Flow
934.1M
↑ 257.97%
FY19Y/Y Change
Operating Cash Flow
-115.0M
↑ 65.9%
Investing Cash Flow
-121.1M
↓ 84.52%
Financing Cash Flow
253.2M
↓ 72.9%
FY20Y/Y Change
Operating Cash Flow
136.5M
↓ 218.67%
Investing Cash Flow
-702.0M
↑ 479.85%
Financing Cash Flow
1.9B
↑ 642.4%
FY21Y/Y Change
Operating Cash Flow
-102.2M
↓ 174.91%
Investing Cash Flow
-1.1B
↑ 54.14%
Financing Cash Flow
8.5M
↓ 99.55%
FY22Y/Y Change
Operating Cash Flow
-223.6M
↑ 118.67%
Investing Cash Flow
74.1M
↓ 106.84%
Financing Cash Flow
76.5M
↑ 802.8%
Q4 FY21Q/Q Change
Operating Cash Flow
-24.6M
↓ 39.74%
Investing Cash Flow
78.4M
↓ 259.29%
Financing Cash Flow
-12.2M
↓ 15156.79%
Q1 FY22Q/Q Change
Operating Cash Flow
-173.8M
↑ 607.12%
Investing Cash Flow
45.6M
↓ 41.91%
Financing Cash Flow
2.7M
↓ 122.43%
Q2 FY22Q/Q Change
Operating Cash Flow
-60.9M
↓ 64.94%
Investing Cash Flow
21.7M
↓ 52.46%
Financing Cash Flow
63.4M
↑ 2218.54%
Q3 FY22Q/Q Change
Operating Cash Flow
-40.9M
↓ 32.82%
Investing Cash Flow
65.0M
↑ 200.13%
Financing Cash Flow
235.0K
↓ 99.63%
Q4 FY22Q/Q Change
Operating Cash Flow
52.0M
↓ 227.15%
Investing Cash Flow
-58.2M
↓ 189.47%
Financing Cash Flow
10.1M
↑ 4199.15%
Q1 FY23Q/Q Change
Operating Cash Flow
-38.2M
↓ 173.44%
Investing Cash Flow
82.9M
↓ 242.61%
Financing Cash Flow
133.6M
↑ 1222.34%

Technicals Summary

Sell

Neutral

Buy

Exact Sciences Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Exact Sciences Corporation
Exact Sciences Corporation
27.51%
84.06%
79.57%
-1.13%
38.44%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
0.28%
11.49%
26.49%
51.84%
115.18%
Agilent Technologies Inc.
Agilent Technologies Inc.
-11.7%
-22.58%
-7.37%
29.71%
86.53%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.67%
-6.65%
-5.92%
49.4%
142.86%
Danaher Corp.
Danaher Corp.
-3.18%
-12.45%
-11.04%
39.0%
130.31%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
9.2%
-4.98%
-8.8%
33.17%
98.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Exact Sciences Corporation
Exact Sciences Corporation
NA
NA
-1.07
-2.0
-0.16
-0.05
0.0
17.0
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
55.87
55.87
7.21
9.69
0.94
0.22
0.0
10.13
Agilent Technologies Inc.
Agilent Technologies Inc.
25.61
25.61
2.36
5.61
0.25
0.1
0.01
19.6
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
28.81
28.81
4.28
23.68
14.48
0.05
0.0
109.55
Danaher Corp.
Danaher Corp.
25.07
25.07
3.24
9.38
0.14
0.06
0.0
68.31
IQVIA Holdings Inc.
IQVIA Holdings Inc.
36.24
36.24
1.48
10.42
0.18
0.05
0.0
31.98
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Exact Sciences Corporation
Exact Sciences Corporation
Buy
$15.1B
38.44%
NA
-23.49%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
Buy
$39.0B
115.18%
55.87
20.38%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$34.3B
86.53%
25.61
19.19%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$200.3B
142.86%
28.81
13.75%
Danaher Corp.
Danaher Corp.
Buy
$171.7B
130.31%
25.07
22.4%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
Buy
$36.9B
98.9%
36.24
7.28%

Institutional Holdings

  • Vanguard Group Inc

    9.67%

  • ARK Investment Management LLC

    6.33%

  • BlackRock Inc

    6.31%

  • Wellington Management Company LLP

    5.70%

  • JPMorgan Chase & Co

    4.31%

  • Capital World Investors

    3.68%

Corporate Announcements

  • Exact Sciences Corporation Earnings

    Exact Sciences Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.

Organization
Exact Sciences Corporation
Employees
6300
CEO
Mr. Kevin T. Conroy
Industry
Health Technology

Discover More

FAQs